טוען...
New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of disease-modifying drugs used for MS act on the inflammatory component of the disease and are approved for use in relap...
שמור ב:
| הוצא לאור ב: | Neuropsychiatr Dis Treat |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5922247/ https://ncbi.nlm.nih.gov/pubmed/29719400 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S147874 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|